Principal Investigator
Robert Kirsner
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231069
Clinical Trial Summary
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other